Friday 26 February | |
ASA International Group PLC | Trading Statement |
FBD Holdings PLC | Full Year Results |
Glenveagh Properties PLC | Full Year Results |
IMI PLC | Full Year Results |
International Consolidated Airlines Group SA | Full Year Results |
Law Debenture Corporation PLC | Full Year Results |
Revolution Bars Group PLC | Half Year Results |
Rightmove PLC | Full Year Results |
RSA Insurance Group PLC | Full Year Results |
VR Education Holdings PLC | Full Year Results |
Avation PLC | Full Year Results |
Monday 1 March | |
AFC Energy PLC | Full Year Results |
Aggreko PLC | Full Year Results |
Bank of Ireland Group PLC | Full Year Results |
Bunzl PLC | Full Year Results |
CentralNic Group PLC | Full Year Results |
Craneware PLC | Half Year Results |
GlobalData PLC | Full Year Results |
Greencoat Renewables PLC | Full Year Results |
Medica Group PLC | Full Year Results |
Mpac Group PLC | Full Year Results |
Quartix Holdings PLC | Full Year Results |
Reach PLC | Full Year Results |
Seplat Petroleum Development Co PLC | Full Year Results |
Tuesday 2 March | |
Apax Global Alpha Ltd | Full Year Results |
Ashtead Group PLC | Q3 Results |
Bluefield Solar Income Fund Ltd | Half Year Results |
Croda International PLC | Full Year Results |
Devro PLC | Full Year Results |
Flutter Entertainment PLC | Full Year Results |
Foxtons Group PLC | Full Year Results |
Fresnillo PLC | Full Year Results |
Hotel Chocolat Group PLC | Half Year Results |
Intertek Group PLC | Full Year Results |
James Fisher & Sons PLC | Full Year Results |
PPHE Hotel Group Ltd | Full Year Results |
Renalytix AI PLC | Half Year Results |
Robert Walters PLC | Full Year Results |
Rotork PLC | Full Year Results |
Signature Aviation PLC | Full Year Results |
Supermarket Income REIT PLC | Half Year Results |
Taylor Wimpey PLC | Full Year Results |
Travis Perkins PLC | Full Year Results |
Uniphar PLC | Full Year Results |
Weir Group PLC | Full Year Results |
XP Power Ltd | Full Year Results |
Wednesday 3 March | |
Avast PLC | Full Year Results |
Biffa PLC | Trading Statement |
GetBusy PLC | Full Year Results |
Hiscox Ltd | Full Year Results |
International Personal Finance PLC | Full Year Results |
Nichols PLC | Full Year Results |
PageGroup PLC | Full Year Results |
Persimmon PLC | Full Year Results |
Polymetal International PLC | Full Year Results |
Prudential PLC | Full Year Results |
Vivo Energy PLC | Full Year Results |
Thursday 4 March | |
Aviva PLC | Full Year Results |
Admiral Group PLC | Full Year Results |
Capital & Regional PLC | Full Year Results |
Coats Group PLC | Full Year Results |
CRH PLC | Full Year Results |
Entain PLC | Full Year Results |
Franchise Brands PLC | Full Year Results |
Galliford Try Holdings PLC | Half Year Results |
Hunting PLC | Full Year Results |
Hutchison China MediTech Ltd | Full Year Results |
John Laing Group plc | Full Year Results |
Meggitt PLC | Full Year Results |
Melrose Industries PLC | Full Year Results |
Morgan Advanced Materials PLC | Full Year Results |
Rathbone Brothers PLC | Full Year Results |
Rentokil Initial PLC | Full Year Results |
Schroders PLC | Full Year Results |
Spire Healthcare Group PLC | Full Year Results |
Synthomer PLC | Full Year Results |
Tyman PLC | Full Year Results |
Vesuvius PLC | Full Year Results |
Vistry Group PLC | Full Year Results |
William Hill PLC | Full Year Results |
Copyright 2021 Alliance News Limited. All Rights Reserved. |
IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag
Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.
Read more